Invitrogen's Life Technolgies Buy Builds Life Science/Genomics Offerings
This article was originally published in The Gray Sheet
Executive Summary
The acquisition of Life Technologies, under a definitive $1.9 bil. agreement announced July 9, will enhance Invitrogen's life sciences and genomics product offerings, create a combined firm with revenues of over $500 mil. and about $100 mil. in operating cash flow, and generate anticipated cash earnings per share growth "in the range of 20-25%," Invitrogen says.